Denise Laurienti, MD
Nephrology · Winston-Salem, NCNPI 1023017563
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,448, more than ten times the $37 reported in 2019.
Across 144 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$427
- AstraZeneca$299
- Novo Nordisk$226
- Travere Therapeutics, Inc.$216
- Mallinckrodt Hospital Products Inc.$206
- GSK$193
- plus $1K from 20 others
Across 83 payments — averaging $755.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$63K
What the payments were for
- Food & beverage$2,61195%
- Education$1405%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $427 |
| AstraZeneca(2 entities) | 13 | $299 |
| Novo Nordisk | 12 | $226 |
| Travere Therapeutics, Inc. | 10 | $216 |
| Mallinckrodt Hospital Products Inc. | 10 | $206 |
| GSK | 12 | $193 |
| Otsuka America Pharmaceutical, Inc. | 8 | $187 |
| Amgen(2 entities) | 9 | $146 |
| Akebia Therapeutics Inc | 7 | $114 |
| Boehringer Ingelheim | 7 | $114 |
| Vifor Pharma, Inc. | 4 | $101 |
| Bayer | 4 | $71 |
| ANI Pharmaceuticals, Inc. | 4 | $61 |
| Calliditas Therapeutics US Inc. | 3 | $53 |
| Lilly USA, LLC | 3 | $51 |
| Scpharmaceuticals Inc. | 2 | $43 |
| Apellis Pharmaceuticals, Inc. | 2 | $35 |
| Fresenius USA Marketing, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Veloxis Pharmaceuticals, Inc. | 1 | $26 |
| Baxter Healthcare | 1 | $22 |
| OPKO Pharmaceuticals, LLC | 1 | $20 |
| Teleflex LLC | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
How this compares
$2,751 in reported general payments places this provider in the 65th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 76 | $61,144 |
| FarxigaDapagliflozin Propanediol | 51 | $35,138 |
| EliquisApixaban | 32 | $27,502 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $14,248 |
| Sevelamer Carbonate | 111 | $11,733 |
| ProsolParenteral Amino Acid 20% No.1 | 46 | $8,214 |
| Labetalol Hcl | 104 | $4,977 |
| Eplerenone | 16 | $1,940 |
| Calcium Acetate | 28 | $1,936 |
| Potassium Citrate ErPotassium Citrate | 19 | $1,871 |
| Nifedipine ErNifedipine | 68 | $1,452 |
| Midodrine Hcl | 18 | $1,348 |
| Hydralazine Hcl | 111 | $1,281 |
| Amlodipine Besylate | 209 | $1,156 |
| Losartan Potassium | 133 | $1,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $114 | $61,14476 claims |
| AstraZenecaFarxiga, Lokelma | $299 | $49,38671 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 366 nephrology providers in North Carolina.
Other nephrology in Winston-Salem
- Gregory GreenwoodWinston-Salem$947K
- Michael EtomiCharlotte$212K
- William KendrickGreenville$125K
- Jason EckelCary$123K
- Raven VooraSanford$111K
- Nam VoAsheville$89K
- Jennifer StoddardPinehurst$77K
- Barry FreedmanWinston Salem$67K
- James McCabeWilmington$56K
- Sammy MoghaziRaleigh$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.